Geographic proximity to buprenorphine treatment providers in the U.S.

The ISSUP activities funded by the U.S. Department of State are temporarily suspended.
This website will remain live, but ISSUP is not currently monitoring or updating it. No new membership applications will be accepted or reviewed, no posts or comments will be possible, and members cannot login.
This information will be updated with any change in circumstances. Thank you for your understanding.

Back to Medication Assisted Treatment (MAT) main page

Source:

Langabeer, J., Stotts, A. L., Cortez, A., Tortolero, G., & Champagne-Langabeer, T. (2020). Geographic proximity to buprenorphine treatment providers in the US. Drug and alcohol dependence, 108131.

Highlights

•Access to treatment remains a concern for patients with opioid use disorder.
•Geospatial buffering model estimates 28 million Americans outside 10 miles.
•Central and western U.S. region persist with high ratios between need and providers.
•Low access to transportation, long distances equate to lower engagement in treatment.

Geographic proximity to buprenorphine treatment providers in the US.pdf

ISSUP members can join Networks to comment – Sign in or become a member